Hemanshu (Hem) Pandya – President and Chief Executive Officer
Hemanshu (Hem) Pandya – President and Chief Executive Officer
Mr. Pandya is an experienced pharmaceutical executive with a broad spectrum of commercial, operational, strategic and corporate development experience. Previously, Mr. Pandya was President and Chief Executive Officer of IGI Laboratories Inc. (NYSE AMEX: IG) a provider of topical formulation development, analytical, manufacturing and packaging services to the pharmaceutical industry. Prior to IGI, Mr. Pandya was Chief Operating Officer of NexMed Inc. (now Apricus Biosciences Inc – NASDAQ: APRI), responsible for R&D, Operations, and Corporate Development. He has also served in various senior management roles within the pharmaceutical industry including Senior Vice President of Business Development and Strategic Alliances for Andrx Pharmaceuticals (now Watson Pharmaceuticals – NYSE : WPI), Chief Commercial Officer for Putney, Inc., and senior management roles with Able Laboratories, Inc., Ivax Pharmaceuticals, Inc. (now Teva Pharmaceuticals Industries Limited – NYSE : TEVA) and Faulding/Purepac Pharmaceutical Company (now Actavis, Inc.).

Kamlesh Haribhakti – Executive Vice President and Chief Scientific Officer
Mr. Haribhakti has extensive experience in all aspects of pharmaceutical development including formulations, analytical, pharmacokinetics, and regulatory. Mr. Haribhakti has been responsible for successfully developing, filing, and obtaining FDA approval for over 100 generic pharmaceutical products. Previously, Mr. Haribhakti was Managing Director of Dinesh Remedies Limited (DRL). Prior to DRL, Mr. Haribhakti was a Co-Founder and Chief Executive Officer of KVD Pharma until its sale to Amneal Pharmaceuticals in Dec. 2007. He has also served in R&D roles for several pharmaceutical companies throughout his career including Able Laboratories, Inc., McNeil Pharmaceuticals (a Johnson & Johnson company), Eon Laboratories, Inc. (now Sandoz, a Novartis Company), Faulding/Purepac Pharmaceutical Company (now Actavis, Inc.), and Ivax Pharmaceuticals, Inc. (now Teva Pharmaceuticals Industries Limited).

Josh Gordon – Senior Vice President of Sales, Marketing and Commercial Operations
Mr. Gordon is an experienced pharmaceutical executive with a broad array of commercial, operational, strategic and financial experience. Mr. Gordon served in various senior and progressive management roles in the generic pharmaceutical industry including Vice President/General Manager, Specialty Pharmaceuticals at Hospira, Senior Vice President of Purchasing and Operations at Anda, a unit of Andrx Pharmaceuticals (now Actavis) and Vice President of Generic Product Purchasing at Cardinal Health. Prior to joining Vensun, Mr. Gordon was a Vice President at Baxter International, Inc. in their medical products division. Mr. Gordon received his Bachelor’s degree from the University of Pennsylvania’s Wharton School of Business. He earned a Masters of Professional Accounting degree from The University of Miami Graduate School of Business. Mr. Gordon is a Certified Public Accountant.

Jatin Desai, Ph.D. – Executive Director, R&D and Technical Operations
Dr. Desai is an executive with over 25 years of experience in generic, branded and OTC product development, clinical research and commercialization of products ranging from solid dosage to injectables. His area of expertise is in modified release dosage forms. Dr. Desai has three granted patents and several additional applications under review. Previously, Dr. Desai was the Vice President, Technical Operations at AustarPharma. Prior to AustarPharma, he served in various senior roles as Director of Formulation Research at Zydus Pharmaceuticals, and Vice president Technical Operations at Morepen Laboratories. Dr. Desai holds a Masters of Science degree in Pharmaceutics and Industrial Pharmacy from Lallubhai Motilal College of Pharmacy, India, and a Doctorate in Pharmaceutics from North Gujarat University, India.

Donna M. Cordasco – Senior Director of Quality and Compliance
Ms. Cordasco has over 25 years of diverse experience in pharmaceutical R&D and quality management.  Prior to joining Vensun, Ms. Cordasco was Director of Laboratory QA for the International AIDS Vaccine Initiative, a non-profit organization engaged in novel research and vaccine development.  Her generic pharmaceutical industry experience includes roles as Head of QA/QC & Regulatory at IGI Laboratories, Inc (AMEX: IG) and Director of QA/QC at Sun Pharmaceuticals Industries, Inc. While at Faulding/Purepac Pharmaceutical Company (now Actavis, Inc – NYSE: ACT), she served in several senior management roles including Director of QC, Director of Analytical Services and in various project management, strategic planning, and process improvement  roles. Early in her career, Ms. Cordasco served as an Adjunct Professor in Organic and Biochemistry. Ms. Cordasco has a Bachelor of Science degree in Biochemistry from the University of New Hampshire and a Masters of Science degree in Biochemistry and Molecular Biology from New York University.

George Sager – Director of Operations
Mr. Sager has more than 30 years of Financial and Operational experience. Prior to joining Vensun, Mr. Sager was Controller at Medicia Holdings, LLC, where he managed the day-to-day finance and accounting functions for the contract manufacturer serving the Health and Beauty Industry. Previously, Mr. Sager was Vice President of Finance for Glenmark Pharmaceuticals and has held various positions with companies such as Able Laboratories, Inc., Lederle Laboratories, Asea Brown Boveri, IVC Industries and Guerlain, Inc. Mr. Sager holds a MBA in Finance from Fairleigh Dickinson University and a Bachelor of Science degree in Accounting from Ramapo College.

Rajeev Mohan, Ph.D. – Director of Strategic Development
Dr. Mohan has extensive experience in product development, scale-up, manufacturing, business strategy, product lifecycle management, alliance management and product commercialization. Prior to joining Vensun, Dr. Mohan was Manager of Strategic Analytics supporting the sales and marketing team at Mutual/URL Pharma (now Takeda – NYSE:TKPHF) including the commercial assessment of business development projects. Prior to Mutual, he served in various technical and operational roles including Manager of Manufacturing Systems and Cost Management at Andrx Pharmaceuticals, Inc. (now Actavis – NYSE:ACT).  Dr. Mohan holds a MBA from Cornell University, a Doctorate in Chemical Engineering from Polytechnic University (NYU) and a Bachelor of Science degree in Chemical Engineering from Osmania University, India.

Nitin V. Kotak – Senior Director of Finance
Mr. Kotak is an accomplished and well-rounded finance and business leader with more than 35 years of experience. His broad areas of expertise include financial strategy, budgetary control and variance analysis, analytical insights from data, implementation and improvement of ERP systems and automated controls, crisis management, reorganizations, governance, compliance, process improvement, and collaboration. Mr. Kotak has extensive global experience across various industries, including in pharmaceuticals and healthcare. Previously, Mr. Kotak was the Chief Financial Officer and Treasurer at Howard Hughes Medical Institute, with an endowment of $19 billion and an annual budget of $1 billion. Throughout his executive career, Mr. Kotak has held leadership positions with HHMI, Technest Holdings Inc, Able Laboratories Inc, Mattel Inc, ITC Limited, and The Tinplate Company of India Limited. Mr. Kotak holds a Bachelor of Commerce in Accounting & Auditing (with Honors) from the University of Calcutta; he is an FCA, FCMA, and FCS, and has been awarded two gold medals; he attended a course on Endowment Management at the Yale School of Management, and received additional Best Practices Training. He has served on the Board of Directors for Mattel India; as Ex-Chairman of the American Center of Cost Accountants of India; is a Co-founder, Trustee, and Treasurer of Kolkata Foundation, and Operations Trustee and Ex-President of the Washington Kali Temple and Center for Human Development. In addition, Mr. Kotak has addressed the Euro Finance Conference in Singapore.